Immuno-oncology Research
Immuno-oncology Research - Related Videos
08:17
A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research
0 Views •
Cited by 6 •
2019
We describe a human peripheral blood mononuclear cell (PBMC) — based humanized xenograft mouse model for translational immuno-oncology research. This protocol could serve as a general guideline for establishing and characterizing similar models for I-O therapy assessment.
10:49
Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens
0 Views •
Cited by 37 •
2019
A detailed protocol for a six-marker multiplex immunofluorescence panel is optimized and performed, using an automated stainer for more consistent results and a shorter procedure time. This approach can be directly adapted by any laboratory for immuno-oncology studies.
11:18
Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research
0 Views •
Cited by 5 •
2011
A thoracic oncology database was developed to serve as a comprehensive repository for clinical and laboratory data for the purposes of translational research. The database will serve translational cancer researchers within the Thoracic Oncology Research Program. This database is adaptable to other cancer models, as well as other human diseases.
08:57
Peptide and Protein Quantification Using Automated Immuno-MALDI (iMALDI)
0 Views •
Cited by 13 •
2017
A protocol for the protein quantification in complex biological fluids using automated immuno-MALDI (iMALDI) technology is presented.
06:37
Multispectral Real-time Fluorescence Imaging for Intraoperative Detection of the Sentinel Lymph Node in Gynecologic Oncology
0 Views •
Cited by 41 •
2010
Fluorescence imaging is a promising innovative modality for image-guided surgery in surgical oncology. In this video we describe the technical procedure for detection of the sentinel lymph node using fluorescence imaging as showcased in gynecologic oncologicy. A multispectral fluorescence camera system, together with the fluorescent agent indocyanine green, is applied.
FAQs
Tumor antigen presentation provides the immune system with molecular information that can distinguish cancer cells from surrounding tissue. Immuno-oncology research examines whether these antigens are effectively displayed and recognized, because recognition alone may not produce a strong response. Findings in this area help explain differences in immune activity and guide strategies designed to improve antitumor T-cell activation.
Immune checkpoints can limit T-cell activity and prevent excessive immune responses, but tumors may exploit these regulatory pathways to avoid attack. Research therefore evaluates how checkpoint signaling contributes to immune suppression and whether blocking it restores antitumor activity. This mechanism is central to understanding why checkpoint-directed treatments can produce substantial responses in some cancers but not others.
The tumor microenvironment includes the local conditions surrounding cancer cells and can suppress immune responses or reduce immune-cell effectiveness. Immuno-oncology studies investigate these interactions to clarify why immune recognition does not always lead to tumor control. Understanding this environment supports research into therapies and combinations intended to overcome resistance rather than targeting cancer cells in isolation.
Response differences can reflect variation in antigen presentation, T-cell activation, checkpoint activity, and immune suppression within the tumor microenvironment. Immuno-oncology research connects these mechanisms with treatment outcomes to identify measurable features associated with sensitivity or resistance. This work supports biomarker discovery, helping researchers investigate which patients may be more likely to achieve durable clinical responses.
Cancer research evaluates these treatment classes according to how they direct or strengthen antitumor immunity. Checkpoint inhibitors target immune regulatory mechanisms, cancer vaccines aim to support recognition of tumor-associated targets, and adoptive cell therapies use immune cells as a therapeutic strategy. Studies assess their effects individually or within broader treatment plans to determine which approaches produce meaningful immune and clinical responses.
Combination regimens are studied because different treatments may address separate barriers to effective antitumor immunity. One approach may improve immune recognition, while another may counter suppressive signaling or strengthen immune-cell activity. Evaluating combinations helps researchers determine whether coordinated treatment can overcome resistance and produce more durable responses than a single strategy, while also clarifying which mechanisms contribute to the outcome.
Biomarker studies seek measurable indicators linked to immune activity, treatment sensitivity, or resistance. In immuno-oncology, these investigations may connect tumor antigen presentation, T-cell activation, checkpoint regulation, or microenvironmental suppression with observed outcomes. The resulting information can help classify response patterns and support personalized cancer care by linking treatment decisions more closely to the biology of an individual tumor.
By examining why tumors differ in immune recognition, suppression, and treatment response, immuno-oncology research provides a biological basis for tailoring therapy. Researchers can use findings about biomarkers, resistance mechanisms, and response durability to compare treatment options or combinations for particular tumor characteristics. This approach aims to move beyond uniform treatment strategies and improve the likelihood of sustained clinical benefit.